No robot has ever cut into a patient in the United States without a surgeon's hands directly on the controls at every moment. The Food and Drug Administration wants to know what happens when that changes, and it has given the robotic surgery industry until January 5, 2027, to weigh in.
On November 6, the FDA's Center for Devices and Radiological Health published a discussion paper titled 'Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities.' The agency will also hold a two-day public workshop on December 2 and 3 at its White Oak campus in Silver Spring, Maryland, according to the FDA.
The agency is careful to note the paper carries no regulatory weight yet. It 'does not represent draft or final guidance,' the FDA states, and proposes no specific policy. Instead it opens four lines of discussion: how regulators should define 'autonomous' and 'remote teleoperation' in the first place, the benefit-risk calculus unique to devices that act without a human at the controls, the separate calculus for devices controlled from a distance, and the mitigations manufacturers might need to build in before either reaches a patient.
A Market Already Racing Toward the Question
The paper did not appear in a vacuum. It follows draft guidance the FDA issued in September covering nonclinical testing, clinical data and labeling requirements for robotically-assisted surgical devices generally, with comments on that earlier document due November 24. Taken together, the two filings suggest the agency is building a tiered regulatory structure: baseline rules for today's surgeon-operated systems, and a second track for the autonomous and remote systems now in development.
That second track has real companies waiting on it. Intuitive Surgical's da Vinci remains the dominant platform, but Medtronic's Hugo, Stryker's Mako, CMR Surgical's Versius and Medical Microinstruments' Symani have all pushed into the market in recent years, narrowing Intuitive's lead. Researchers at Johns Hopkins have already demonstrated a robot performing autonomous gallbladder removal on animal tissue, and telesurgery programs, including one led by Dr. Vipul Patel at AdventHealth, have shown that surgeons can operate on patients hundreds of miles away. None of those capabilities currently has a clear regulatory pathway to a cleared product in the U.S.
What Happens Between Now and January
For device makers, the comment period is less a formality than a chance to shape definitions that will govern years of product development. A company building a semi-autonomous suturing module, for instance, has a direct stake in how the FDA ultimately distinguishes 'autonomous' from merely 'automated,' since that line will determine which clinical evidence bar it has to clear.
The FDA says device manufacturers, regulatory professionals, surgeons, hospital administrators and patients are all invited to submit comments through Regulations.gov under docket number FDA-2026-N-13135. The December workshop will revisit the same four topics in person and virtually, giving the agency a public record to draw on before it moves toward actual guidance.
No timeline for that next step has been set. But with multiple surgical robot makers already testing autonomy in research settings, the discussion paper marks the first time the FDA has formally signaled it is preparing to regulate robots that operate, even partially, without a surgeon's hand on the controls.